ATE322278T1 - Verbindungen aus phyllanthus zur prävention und/oder behandlung von erkrankungen im zusammenhang mit einem retrovirus - Google Patents

Verbindungen aus phyllanthus zur prävention und/oder behandlung von erkrankungen im zusammenhang mit einem retrovirus

Info

Publication number: ATE322278T1
Authority: AT; Austria
Prior art keywords: retrovirus; phyllanthus; prevention; treatment; compounds
Prior art date: 2000-10-06

Application number

AT01986262T

Other languages

English (en)

Inventor

Ralf Wagner

Frank Notka

Original Assignee

Phytrix Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-06

Filing date

2001-10-05

Publication date

2006-04-15

2001-10-05 Application filed by Phytrix Ag filed Critical Phytrix Ag

2006-04-15 Application granted granted Critical

2006-04-15 Publication of ATE322278T1 publication Critical patent/ATE322278T1/de

Links

241001430294 unidentified retrovirus Species 0.000 title abstract 5
241001130943 Phyllanthus <Aves> Species 0.000 title abstract 3
201000010099 disease Diseases 0.000 title abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
230000002265 prevention Effects 0.000 title abstract 2
150000001875 compounds Chemical class 0.000 title 1
229920002824 gallotannin Polymers 0.000 abstract 4
TUSDEZXZIZRFGC-XIGLUPEJSA-N corilagin Chemical compound O([C@H]1[C@H](O)[C@H]2OC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC[C@@H](O1)[C@H]2O)C(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-XIGLUPEJSA-N 0.000 abstract 3
241000725303 Human immunodeficiency virus Species 0.000 abstract 2
LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 abstract 2
239000003112 inhibitor Substances 0.000 abstract 2
JMGCAHRKIVCLFW-UHFFFAOYSA-N 1-O-Galloylcastalagin Natural products Oc1cc(cc(O)c1O)C(=O)OC2C3OC(=O)c4c2c(O)c(O)c(O)c4c5c(O)c(O)c(O)c6c5C(=O)OC3C7OC(=O)c8cc(O)c(O)c(O)c8c9c(O)c(O)c(O)cc9C(=O)OCC7OC(=O)c%10cc(O)c(O)c(O)c6%10 JMGCAHRKIVCLFW-UHFFFAOYSA-N 0.000 abstract 1
TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 abstract 1
229920002786 Corilagin Polymers 0.000 abstract 1
JQQBXPCJFAKSPG-SVYIMCMUSA-N Geraniin Chemical compound OC1=C(O)C(O)=CC(C(=O)O[C@H]2[C@@H]3OC(=O)C=4C=C(O)C(O)=C5O[C@@]6(O)C(=O)C=C([C@@H](C5=4)C6(O)O)C(=O)O[C@H]4[C@@H]3OC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC[C@H]4O2)=C1 JQQBXPCJFAKSPG-SVYIMCMUSA-N 0.000 abstract 1
229920000061 Geraniin Polymers 0.000 abstract 1
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 abstract 1
244000173207 Phyllanthus amarus Species 0.000 abstract 1
CPWYQGWOJMNXGJ-UHFFFAOYSA-N corilagin Natural products OC1C2COC(=O)c3c(O)c(O)c(O)c(O)c3c4c(O)c(O)c(O)c(O)c4C(=O)OC1C(O)C(OC(=O)c5cc(O)c(O)c(O)c5)O2 CPWYQGWOJMNXGJ-UHFFFAOYSA-N 0.000 abstract 1
229920001968 ellagitannin Polymers 0.000 abstract 1
JMGCAHRKIVCLFW-CNWXVVPTSA-N ellagitannin Chemical compound OC1=C(O)C(O)=CC(C(=O)O[C@H]2C3=C4C(=O)O[C@@H]2[C@@H]2[C@@H]5OC(=O)C6=CC(O)=C(O)C(O)=C6C6=C(O)C(O)=C(O)C=C6C(=O)OC[C@H]5OC(=O)C5=CC(O)=C(O)C(O)=C5C=5C(O)=C(O)C(O)=C(C=5C(=O)O2)C4=C(O)C(O)=C3O)=C1 JMGCAHRKIVCLFW-CNWXVVPTSA-N 0.000 abstract 1
GJMUCSXZXBCQRZ-UHFFFAOYSA-N geraniin Natural products Oc1cc(cc(O)c1O)C(=O)OC2OC3COC(=O)c4cc(O)c(O)c(O)c4c5cc(C(=O)C67OC3C(O6)C2OC(=O)c8cc(O)c(O)c9OC%10(O)C(C(=CC(=O)C%10(O)O)C7=O)c89)c(O)c(O)c5O GJMUCSXZXBCQRZ-UHFFFAOYSA-N 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Natural Medicines & Medicinal Plants (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Virology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Engineering & Computer Science (AREA)
Medical Informatics (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Alternative & Traditional Medicine (AREA)
Biotechnology (AREA)
Botany (AREA)
Mycology (AREA)
Microbiology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT01986262T 2000-10-06 2001-10-05 Verbindungen aus phyllanthus zur prävention und/oder behandlung von erkrankungen im zusammenhang mit einem retrovirus ATE322278T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP00121852		2000-10-06
EP01114008		2001-06-08

Publications (1)

Publication Number	Publication Date
ATE322278T1 true ATE322278T1 (de)	2006-04-15

Family

ID=26071484

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01986262T ATE322278T1 (de)	2000-10-06	2001-10-05	Verbindungen aus phyllanthus zur prävention und/oder behandlung von erkrankungen im zusammenhang mit einem retrovirus

Country Status (10)

Country	Link
US (1)	US20040161477A1 (de)
EP (1)	EP1333848B1 (de)
JP (1)	JP2004513092A (de)
AT (1)	ATE322278T1 (de)
AU (1)	AU2002220594A1 (de)
CA (1)	CA2424869A1 (de)
DE (1)	DE60118592T2 (de)
ES (1)	ES2261507T3 (de)
PT (1)	PT1333848E (de)
WO (1)	WO2002028403A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2004510822A (ja)	2000-10-06	2004-04-08	シーエムアイ−センターズ・フォー・メディカル・イノヴェーション・アクチェンゲゼルシャフト	Ｐｈｙｌｌａｎｔｈｕｓ抽出物の製造方法
EP2116253A1 (de) *	2008-05-07	2009-11-11	Phytrix JV, LLC	Neuartiger Phyllanthus-Extrakt
WO2011085454A1 (en) *	2010-01-18	2011-07-21	Katholieke Universiteit Leuven K.U.Leuven R&D	Gp120 -binding benzene compounds and saccharide compounds
KR101604347B1 (ko)	2013-07-01	2016-03-17	한국생명공학연구원	피스타시아 웨인마니폴리아 추출물 또는 이의 분획물을 포함하는 염증성 질환의 예방 또는 치료용 약학 조성물
CN103480178B (zh) *	2013-09-30	2016-09-28	新疆大学	一种亚临界水提取雪菊中活性成分的方法
CN103976356B (zh) *	2014-05-07	2015-08-26	王浩	一种减肥食品及其制备方法
CN110665002B (zh) *	2019-10-29	2023-01-24	信阳市动物疫病预防控制中心	一种用于防治牛病毒性腹泻的抗体制剂及其制备方法
CN111658631A (zh) *	2020-06-11	2020-09-15	广东盛普生命科技有限公司	没食子酸及其衍生物和结构类似物在制备抗冠状病毒药物方面的应用
CN112022867B (zh) *	2020-06-18	2022-05-13	浙江省疾病预防控制中心	老鹳草素在制备抗新型冠状病毒药中的应用
EP3954379A1 (de) *	2020-08-12	2022-02-16	HFM - Hybrid Fusion Medicals, GmbH	Zusammensetzungen mit phyllanthus-extrakt zur verwendung in der behandlung oder vorbeugung einer sars-cov-2-infektion und/oder mindestens eines symptoms von covid-19

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US28754A (en) *		1860-06-19		Congress boot
US33275A (en) *		1861-09-10		Improved pipe-joi-nt
US4388457A (en) *	1982-02-11	1983-06-14	University Patents, Inc.	Phyllanthostatin compounds
US4673575A (en) *	1985-04-26	1987-06-16	Fox Chase Cancer Center	Composition, pharmaceutical preparation and method for treating viral hepatitus
US4937074A (en) *	1988-03-29	1990-06-26	Fox Chase Cancer Center	Method of treating retrovirus infection
WO1990004968A1 (en) *	1988-10-31	1990-05-17	University Of North Carolina At Chapel Hill	Inhibition of human retroviruses
US5854233A (en) *	1993-09-08	1998-12-29	Pharmacy And Therapeutic Advisory Consultancy Ltd.	Method of treating liver disease and like indications with vasodilating agents
US5529778A (en) *	1994-09-13	1996-06-25	Rohatgi; Surendra	Ayurvedic composition for the prophylaxis and treatment of AIDS, flu, TB and other immuno-deficiencies and the process for preparing the same
US5571441A (en) *	1994-11-01	1996-11-05	The Procter & Gamble Company	Nutrient supplement compositions providing physiologic feedback
US5648089A (en) *	1995-07-03	1997-07-15	Shawkat; Tarek	Extract solution and herbal mixture for treatment of hepatitis
US6136316A (en) *	1996-04-17	2000-10-24	Dabur Research Foundation	Hepatoprotective compositions and composition for treatment of conditions related to hepatitis B and E infection
DE19919585A1 (de) *	1999-04-29	2000-12-07	Cmi Ag	Verwendung von Phyllanthus zur Behandlung von oxidativem Streß und anderen Symptomen

2001
- 2001-10-05 PT PT01986262T patent/PT1333848E/pt unknown
- 2001-10-05 JP JP2002532227A patent/JP2004513092A/ja active Pending
- 2001-10-05 ES ES01986262T patent/ES2261507T3/es not_active Expired - Lifetime
- 2001-10-05 AU AU2002220594A patent/AU2002220594A1/en not_active Abandoned
- 2001-10-05 CA CA002424869A patent/CA2424869A1/en not_active Abandoned
- 2001-10-05 US US10/398,379 patent/US20040161477A1/en not_active Abandoned
- 2001-10-05 DE DE60118592T patent/DE60118592T2/de not_active Expired - Lifetime
- 2001-10-05 AT AT01986262T patent/ATE322278T1/de not_active IP Right Cessation
- 2001-10-05 WO PCT/EP2001/011524 patent/WO2002028403A1/en not_active Ceased
- 2001-10-05 EP EP01986262A patent/EP1333848B1/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
DE60118592D1 (de)	2006-05-18
JP2004513092A (ja)	2004-04-30
DE60118592T2 (de)	2007-05-16
US20040161477A1 (en)	2004-08-19
EP1333848A1 (de)	2003-08-13
EP1333848B1 (de)	2006-04-05
ES2261507T3 (es)	2006-11-16
CA2424869A1 (en)	2002-04-11
AU2002220594A1 (en)	2002-04-15
WO2002028403A1 (en)	2002-04-11
PT1333848E (pt)	2006-08-31

Legal Events

Date

Code

Title

Description

2007-02-15

UEP

Publication of translation of european patent specification

Ref document number: 1333848

Country of ref document: EP

2010-07-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
CA2271622A1 (en)	1998-01-15	Antiviral agents from plant extracts and use for treatment of viral infections
EP1328284A4 (de)	2004-07-07	Neue medizinische kräuterzusammensetzung zur behandlung von lebererkrankungen und hiv
ATE264914T1 (de)	2004-05-15	Antivirale proteine, dafür kodierende dna, und deren verwendung
DE60118592D1 (de)	2006-05-18	Verbindungen aus phyllanthus zur prävention und/oder behandlung von erkrankungen im zusammenhang mit einem retrovirus
MX9304837A (es)	1994-05-31	Peptidos capaces de inhibir la actividad de proteasa vih, su preparacion y su uso terapeutico.
EP0376735A3 (de)	1991-05-15	Zusammensetzung zur Kopfhautbehandlung
AP2000001971A0 (en)	2000-12-31	Homogeneous pharmaceutical compositions comprising abacavir, lamivudine and zidovudine.
CA2163348A1 (en)	1994-12-08	Calanolide and Related Antiviral Compounds, Compositions, and Uses Thereof
BR9911523A (pt)	2001-09-18	Composto de efavirenz, composição farmacêutica, método para inibição da replicação por uma transcriptase reversa viralmente codificada e método para tratamento da infecção do hiv
DE69419854D1 (de)	1999-09-09	Arzneimittelzusammensetzung zur Prophylaxe und Behandlung vorzeitigen Samenergusses
GR3024226T3 (en)	1997-10-31	Antiviral naphthoquinone compounds, compositions and uses thereof.
RU2007104774A (ru)	2008-08-20	Комбинация анти-вич ингибиторов обратной транскриптазы и протеазы
GR3030852T3 (en)	1999-11-30	Calanolide antiviral compounds, compositions and uses thereof.
AU2880595A (en)	1996-01-25	Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses
WO2000072833A3 (de)	2001-05-25	Pharmazeutische zubereitungen zur hemmung von spimgomyelinase
ATE78168T1 (de)	1992-08-15	Arzneimittelzusammensetzung zur vorbeugung und behandlung bakterieller und viraler krankheiten.
NO20003866L (no)	2000-07-28	Urte-antiviralt middel
FR2296426A1 (fr)	1976-07-30	Elixir
ATE308333T1 (de)	2005-11-15	Pharmazeutische zusammensetzung zur behandlung von verfrühter ejakulation und/oder von überempfindlichkeit der sexuellen stimulierung
RU93047363A (ru)	1996-10-10	Лечебно-профилактическое средство широкого спектра действия
Narahari et al.	1990	LE-like erythema and periungual telangiectasia among coffee plantation workers.
DK0384308T3 (da)	1993-04-19	Ekstrakt-lægemiddel
IL102815A0 (en)	1993-01-31	Pharmaceutical compositions and method for the treatment of infection caused by the human immunodeficiency virus
BR0207931A (pt)	2004-03-02	Anticorpos naturais ativos contra vìrus hiv
Kumar et al.	2020	Possible character of classical therapeutic rhizome of turmeric for the prevention and the executives of novel corona virus